Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Bunyard (Alderley Edge, United Kingdom), I. Bhamra (Alderley Edge, United Kingdom), K. Eckersley (Alderley Edge, United Kingdom), C. Chaplin (Alderley Edge, United Kingdom), N. Guisot (Alderley Edge, United Kingdom), C. Jones (Alderley Edge, United Kingdom), C. Phillips (Alderley Edge, United Kingdom), R. Armer (Alderley Edge, United Kingdom). Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis.. 589

Member's Comments

No comment yet.

Related content which might interest you: Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 FGF19, a potential innovative target in Idiopathic Pulmonary Fibrosis? Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Combined pirfenidone, proton pump inhibitor and N-acetylcystein (PINPOINT) in IPF: Preliminary results Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020 Year: 2020 The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Biochemical and functional characterization of lysyl oxidase like 2 (LOXL2) inhibitors Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Bromodomain inhibitor JQ1 attenuates TGF-beta-suppressed SOD2 expression and reduces proliferation in human primary pulmonary fibroblasts Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013 SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis Year: 2016 Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014